{"entity":{"id":"guo-jun","kind":"person","name":"Jun Guo","aka":["郭军"],"tldr":"Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved.","summary":"Guo's department at Peking University Cancer Hospital is the largest melanoma unit in Asia; he led the registration study of toripalimab in previously treated melanoma (China's first domestic PD-1 approval, December 2018), trials of toripalimab plus axitinib in mucosal melanoma, and work defining KIT and other targets in acral melanoma. Past president of CSCO.","asOf":"2026-09-10","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20J%5BAuthor%5D%20melanoma%20Peking%20University%20Cancer%20Hospital%20toripalimab"}],"tags":["china"],"related":["csco"],"cancers":["melanoma","rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab"],"companies":[],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor; Department of Renal Cancer and Melanoma, Peking University Cancer Hospital","institutionId":"pku-cancer-hospital","specialisms":["Melanoma","Acral and mucosal melanoma","Renal cell carcinoma","Immunotherapy"],"profiles":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Guo%20J%5BAuthor%5D%20melanoma%20Peking%20University%20Cancer%20Hospital%20toripalimab"}],"papers":[{"title":"Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial","journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/jco.19.00210"},{"title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","journal":"Annals of Oncology","year":2017,"doi":"10.1093/annonc/mdw694"},{"title":"Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification","journal":"Journal of Clinical Oncology","year":2011,"doi":"10.1200/jco.2010.33.9275"}]},"route":"/people/guo-jun/","neighbours":{"institution":[{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}]}}